Posts tagged healthcare
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study

Domain Therapeutics, a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces that the first patient has been dosed with DT-9081, Domain’s proprietary IO asset, in a first-in-human Phase I study.

Read More
AbCellera and AbbVie Partner to Advance New Antibody Therapies

AbCellera announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. The partnership will leverage AbCellera’s antibody discovery and development engine to deliver optimized development candidates for up to five targets selected by AbbVie across multiple indications.

Read More
IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

IMV Inc. today announced positive initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”) who received at least three previous lines of treatment.

Read More
BIOQUÉBEC, MONTRÉAL INVIVO AND SHERBROOKE INNOPOLE JOIN THEIR VOICES IN A LETTER ADDRESSED TO THE PATENTED MEDICINE PRICES REVIEW BOARD (PMPRB)

On December 10th, 2021, BIOQuébec and other players in the life sciences industry in Quebec sent several federal elected officials their serious concerns regarding the coming into force of the PMPRB reform. As leading representatives of the Quebec life sciences sector who actively and strategically contribute to the country's economy, they asked that the implementation of the PMPRB reform be suspended. A year later, on December 5th, 2022, new developments compel Montréal InVivo, Sherbrooke Innopole and BIOQuébec to reiterate this request. A new request for the postponement of the coming into force of new guidelines has therefore been formulated as part of the PMPRB's consultation process.

Read More
Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202

MONTREAL (CANADA) – November 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD).

Read More
BIOQuébec writes an editorial entitled "Innovation is the foundation for improving healthcare" in the latest edition of the BioLAB Business journal

Quebec is rich in innovative companies that strive to do things differently to bring our knowledge and skills to another level. We were delighted to honor our members Jenthera Therapeutics, Repare Therapeutics, Ventus Therapeutics, KisoJi Biotechnology, Valence Discovery and Modelis who all innovate in the field of life sciences for the development of new therapies.

Read More